Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide
2. Gdc-0077
1. Gdc-0077
2. 2060571-02-8
3. Rg6114
4. Gdc0077
5. Ro7113755
6. Inavolisib [usan]
7. L4c1uy2nyh
8. (2s)-2-[[2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]amino]propanamide
9. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide
10. Rg-6114
11. Ro-7113755
12. N~2~-{(4s,11ap)-2-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}-l-alaninamide
13. Propanamide, 2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)-, (2s)-
14. Mfcd31382124
15. Sgeunorsozvtol-cabztgnlsa-n
16. X3n
17. Inavolisib [inn]
18. Unii-l4c1uy2nyh
19. Inavolisib [who-dd]
20. Gtpl9636
21. Chembl4650215
22. Schembl18360780
23. Bdbm295665
24. Amy16810
25. Ex-a2685
26. Nsc800729
27. S8668
28. Us10112932, Compound 101
29. Who 11204
30. Akos040741785
31. At36699
32. Cs-6459
33. Db15275
34. Gdc-0077; Rg6114
35. Nsc-800729
36. Ac-31594
37. Ms-26989
38. Hy-101562
39. A903455
40. Gdc-0077;rg6114;ro-7113755
41. (2s)-2-((2-((4s)-4-(difluoromethyl)-2-oxo-3-oxazolidinyl)-5,6-dihydroimidazo(1,2-d)(1,4)benzoxazepin-9-yl)amino)propanamide
42. (2s)-2-({4-[(4s)-4-(difluoromethyl)-2-oxo-1,3-oxazolidin-3-yl]-9-oxa-3,6-diazatricyclo[8.4.0.0,tetradeca-1(14),2,4,10,12-pentaen-12-yl}amino)propanamide
43. (s)-2-((2-((s)-4-(difluoromethyl)- 2-oxooxazolidin-3-yl)-5,6- Dihydrobenzo[f]imidazo[1,2- D][1,4]oxazepin-9- Yl)amino)propanamide
44. (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)propanamide (gdc-0077)
| Molecular Weight | 407.4 g/mol |
|---|---|
| Molecular Formula | C18H19F2N5O4 |
| XLogP3 | 1.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 5 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 112 |
| Heavy Atom Count | 29 |
| Formal Charge | 0 |
| Complexity | 641 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Phosphoinositide-3 Kinase Inhibitors
Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. (See all compounds classified as Phosphoinositide-3 Kinase Inhibitors.)
Drugs in Development
Details:
FoundationOne®Liquid CDx to be used as a companion diagnostic for Itovebi (inavolisib) for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Itovebi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2024
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves FoundationOne®Liquid CDx As Diagnostic For Itovebi™ in Breast Cancer
Details : FoundationOne®Liquid CDx to be used as a companion diagnostic for Itovebi (inavolisib) for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.
Brand Name : Itovebi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 11, 2024
Details:
Itovebi (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, approved for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: Itovebi
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2024
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Genentech’s Itovebi For Advanced Hormone Receptor-Positive Breast Cancer
Details : Itovebi (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, approved for adults with endocrine-resistant, PIK3CA-mutated HR+/HER2-breast Cancer.
Brand Name : Itovebi
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2024
Details:
GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: GDC-0077
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 29, 2024
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Priority Review for Genentech’s Inavolisib in PIK3CA-mutated Breast Cancer
Details : GDC-0077 (inavolisib) is a PI3K alpha Inhibitor in combination with palbociclib and fulvestran, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 29, 2024
Details:
GDC-0077 (inavolisib) is an oral therapy for PI3Kα inhibition. It is in phase 3 trials for treatment of advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Lead Product(s): Inavolisib,Fulvestrant
Therapeutic Area: Oncology Brand Name: GDC-0077
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Lead Product(s) : Inavolisib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Breakthrough Therapy Designation to Inavolisib for Advanced Breast Cancer
Details : GDC-0077 (inavolisib) is an oral therapy for PI3Kα inhibition. It is in phase 3 trials for treatment of advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2024
Details:
GDC-0077 (inavolisib) is an investigational, highly selective inhibitor and degrader of mutant PI3K alpha. It is being evaluated in combination with palbociclib & fulvestrant for the treatment of HER2-negative breast cancer With a PIK3CA Mutation.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: GDC-0077
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2023
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Genentech’s Inavolisib Combination Reduces the Risk of Disease Progression by 57% in People With...
Details : GDC-0077 (inavolisib) is an investigational, highly selective inhibitor and degrader of mutant PI3K alpha. It is being evaluated in combination with palbociclib & fulvestrant for the treatment of HER2-negative breast cancer With a PIK3CA Mutation.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 08, 2023
Details:
GDC-0077 (inavolisib) is an oral therapy with high in vitro potency and selectivity for PI3Kα inhibition. It is being evaluated in phase 3 trials for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: GDC-0077
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GDC-0077 (inavolisib) is an oral therapy with high in vitro potency and selectivity for PI3Kα inhibition. It is being evaluated in phase 3 trials for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3C...
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
GDC-0077 (inavolisib palbociclib fulvestrant) is a PI3K alpha Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer with a PIK3CA mutation via oral tablet.
Lead Product(s): Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area: Oncology Brand Name: GDC-0077
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Inavolisib,Palbociclib,Fulvestrant
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : GDC-0077 (inavolisib palbociclib fulvestrant) is a PI3K alpha Inhibitor Small molecule drug candidate, which is currently being evaluated for the treatment of HR+/HER2-breast Cancer with a PIK3CA mutation via oral tablet.
Brand Name : GDC-0077
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info : RX
Registration Country : USA
Brand Name : ITOVEBI
Dosage Form : TABLET;ORAL
Dosage Strength : 3MG
Packaging :
Approval Date : 2024-10-10
Application Number : 219249
Regulatory Info : RX
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : ITOVEBI
Dosage Form : TABLET;ORAL
Dosage Strength : 9MG
Packaging :
Approval Date : 2024-10-10
Application Number : 219249
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
RLD : Yes
TE Code :
Brand Name : ITOVEBI
Dosage Form : TABLET;ORAL
Dosage Strength : 3MG
Approval Date : 2024-10-10
Application Number : 219249
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : ITOVEBI
Dosage Form : TABLET;ORAL
Dosage Strength : 9MG
Approval Date : 2024-10-10
Application Number : 219249
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
Patents & EXCLUSIVITIES
US Patents
Patent Expiration Date : 2036-07-01
US Patent Number : 9650393
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219249
Patent Use Code : U-4024
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-07-01
Patent Expiration Date : 2030-09-27
US Patent Number : 8343955
Drug Substance Claim :
Drug Product Claim :
Application Number : 219249
Patent Use Code : U-4024
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-09-27
Patent Expiration Date : 2030-09-27
US Patent Number : 8343955
Drug Substance Claim :
Drug Product Claim :
Application Number : 219249
Patent Use Code : U-4024
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-09-27
Patent Expiration Date : 2030-09-27
US Patent Number : 8242104
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219249
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-09-27
Patent Expiration Date : 2036-07-01
US Patent Number : 10851091
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219249
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-07-01
Patent Expiration Date : 2038-04-26
US Patent Number : 11028100
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219249
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2038-04-26
Patent Expiration Date : 2036-07-01
US Patent Number : 11760753
Drug Substance Claim :
Drug Product Claim :
Application Number : 219249
Patent Use Code : U-4024
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-07-01
Patent Expiration Date : 2036-07-01
US Patent Number : 10851091
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219249
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-07-01
Patent Expiration Date : 2036-07-01
US Patent Number : 11760753
Drug Substance Claim :
Drug Product Claim :
Application Number : 219249
Patent Use Code : U-4024
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2036-07-01
Patent Expiration Date : 2030-09-27
US Patent Number : 8242104
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 219249
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2030-09-27
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
